Navigation Links
TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
Date:4/2/2009

LA JOLLA, Calif., April 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that on March 31, 2009 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the Company that based on the Company's stockholders' equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2008, the Company does not comply with the minimum stockholders' equity requirement of $10 million for continued listing on The Nasdaq Global Market as set forth in NASDAQ Marketplace Rule 4450(a)(3).

The Company has until April 15, 2009 to provide a specific plan to achieve and sustain compliance with all of the Nasdaq Global Market continued listing requirements, including a time frame for completion of the plan. The Nasdaq letter has no immediate effect on the listing of the Company's common stock.

In the event that the Company receives notice that its common stock is being delisted from the Nasdaq Global Market, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a Nasdaq Listing Qualifications Panel. Alternatively, Nasdaq may permit the Company to transfer its common stock to the Nasdaq Capital Market if it satisfies the requirements for continued listing on that market.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, acute and chronic pain, and xerostomia. The company currently has three clinical stage product candidates:
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
3. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
4. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
5. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
6. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
7. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
8. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
9. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
10. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
11. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced today ... Officer, will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. ... the presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a ...
(Date:9/2/2014)... 2014 Culot brings life science ... management services  BioData, producer of Labguru, the ... announce the appointment of Louis Culot as ... VP Marketing and Business Development at BioDiscovery Inc., developer ... applications. Previously, Culot worked for 17 years ...
(Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
(Date:8/29/2014)... Aug. 29, 2014  Pfenex Inc. (NYSE MKT: ... development of high-value and difficult to manufacture proteins ... and reported financial results for the second quarter ... successful completion of our initial public offering, we ... biosimilar product candidates, derived from our proprietary protein ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Axial Biotech, Inc., a company,revolutionizing spine care ... technologies, announced today that it has met several,major ... genetic,prognostic test for Adolescent Idiopathic Scoliosis (AIS) and ... B financing. The Series B financing was,led by ...
... The rating,agency Moody,s has raised the rating ... "Outlook stable"., As a result, the Group,s ... are substantially enhanced. Moody,s justifies,this step by reference ... of successful acquisitions and in view of the ...
... Conference Call/Webcast to be Wednesday, March 19 at 10:00 ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) will host a ... and year ended December 31,2007 on Wednesday, March 19, ... the conference call can be accessed through the,company,s Web ...
Cached Biology Technology:Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2Moody's Raises Rating for Gerresheimer 2Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results 2
(Date:9/2/2014)... From AGU,s blogs: Earthquake rupture through a U.S. suburb ... University of California Davis in the hours and days ... helping scientists understand why the earthquake caused so much ... The Trembling Earth blog, hosted by the American Geophysical ... Future Mars Rovers: The Next Places to Direct Our ...
(Date:9/2/2014)... September 3, The Field Museum will present the prestigious ... of his commitment to biodiversity conservation awareness. The Parker/Gentry ... an outstanding individual, team or organization whose efforts have ... natural heritage and whose actions can serve as a ... of Mongabay.com, an environmental science and conservation news website ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... toward EAC standard by providing ... a single platform, DALLAS, Sept. 10 As ... globe, many seek a method,to deploy border security capabilities ... ENTU ) and 3M (NYSE: MMM ),announce ...
... ,Empowering People & Commerce, WALL, N.J., Sept. ... a leader in finger-based biometric,identification and wireless public ... 2008 Biometric Technology Expo, to be held in,conjunction ... 23 - 25 at the Tampa Convention Center ...
... been awarded $1 million from the US Department of ... conversion technologies. The grant is one of six awarded ... their advanced biofuels projects. In total, the DOE will ... for their research into how non-food feedstocks can be ...
Cached Biology News:Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 2Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 3Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution 4BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 2BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo 3Stevens awarded $1M for advanced biofuels research 2
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
...
...
Biology Products: